Cerebral Therapeutics, Inc.
12635 E. Montview Boulevard
Aurora
Colorado
80010
United States
Tel: 303-547-3448
Fax: 303-547-3448
Website: http://www.cerebraltherapeutics.com
About Cerebral Therapeutics, Inc.
Cerebral Therapeutics, LLC is a privately-held company founded with the goal of addressing the well-recognized limitations of existing treatments for uncontrolled neurological diseases. Cerebral Therapeutics is combining advanced micro-dosing technology with proprietary medications to precisely deliver treatments to the other side of the blood-brain barrier to improve the lives of patients with uncontrolled neurological disease. With a promising route of administration, Cerebral Therapeutics offers a new approach to managing neurological diseases by means of delivering ideal dosing to targeted sites within the brain. Initially, Cerebral Therapeutics is focused on improving outcomes and propagation in the brain. Future cerebral therapeutic areas include obesity, Alzheimer's disease, Parkinson's disease, anxiety spectrum disorder, and brain cancer. LEADERSHIP:CEO: Daniel J. Abrams
14 articles about Cerebral Therapeutics, Inc.
-
Cerebral Therapeutics Names Julie Foster as Chief Operating Officer
1/25/2023
Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today the appointment of MedTech industry veteran Julie Foster as Chief Operating Officer.
-
This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.
-
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
6/28/2022
Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management.
-
Cerebral Therapeutics, Inc. Names Guy Anthony as Chief Financial Officer
8/3/2021
Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological disease, has appointed Guy Anthony as Chief Financial Officer.
-
Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Trial in Epilepsy
11/17/2020
Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, today announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy. T
-
Cerebral Therapeutics Appoints Stephen J. Farr as Chairman and Welcomes Stephen D. Collins to the Board of Directors
11/10/2020
Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, has appointed Stephen J. Farr, PhD as Chairman of the board of directors. Dr. Farr is the Co-Founder, President, and Chief Executive Officer of Zogenix, a biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and thei
-
Cerebral Therapeutics Completes $35 Million Series B Financing
1/7/2020
Cerebral Therapeutics, a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases, announced today a $35 million Series B financing led by RA Capital Management, with participation from additional new investor Perceptive Advisors and existing investors Vivo Capital, LLC and Granite Point Capital Management, L.P.
-
Cerebral Therapeutics Names John Foster as President and Chief Operating Officer
9/24/2019
Strategic Appointment Highlights Strength of Development and Commercial Experience of Cerebral's Leadership Team
-
Cerebral Therapeutics™ to Present Clinical Data at Antiepileptic Drug and Device Trials XV Conference
5/16/2019
Cerebral Therapeutics™ announced that the Company will present at the Antiepileptic Drug and Device Trials XV conference, which is held every two years and is sponsored by The Epilepsy Study Consortium in collaboration with the University of Pennsylvania and the Epilepsy Foundation.
-
Cerebral Therapeutics Strengthens Clinical Development Leadership with Strategic Appointments
4/16/2019
Lisa Shafer, Ph.D., Chief Scientific Officer, and Eric Distad, Vice President of Clinical Development, add Extensive CNS Drug-Device Development Experience
-
Cerebral Therapeutics Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory Epilepsy
3/8/2019
Cerebral Therapeutics announced the closing of a $7.8 million Extension of its Series A financing by institutional investors Granite Point Capital Management, L.P., and Vivo Capital, LLC. This brings the total Series A investment to $11 million.
-
Cerebral Therapeutics Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy
6/20/2018
Financing Led by Granite Point Capital and Vivo Capital
-
Flowonix And Cerebral Therapeutics Announce Fifth Implant Of First-Of-A-Kind Implantable Drug Therapy To Treat Patients With Refractory Epilepsy
10/3/2017
-
Flowonix And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy
3/15/2017